scholarly journals Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents

2009 ◽  
Vol 30 (5) ◽  
pp. 423-435 ◽  
Author(s):  
A. AKBAR ◽  
J. R. F. WALTERS ◽  
S. GHOSH
Keyword(s):  
Irritable Bowel Syndrome ◽  
Molecular Mechanisms ◽  
Therapeutic Agents ◽  
Review Article ◽  
Visceral Hypersensitivity ◽  
Irritable Bowel

scholarly journals Electroacupuncture Relieves Visceral Hypersensitivity by Inactivating Protease-Activated Receptor 2 in a Rat Model of Postinfectious Irritable Bowel Syndrome

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Wanli Xu ◽  
Mengqian Yuan ◽  
Xiaoliang Wu ◽  
Hao Geng ◽  
Lu Chen ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Rat Model ◽  
Analgesic Effect ◽  
Molecular Mechanisms ◽  
Critical Role ◽  
Visceral Hypersensitivity ◽  
Mrna Levels ◽  
Irritable Bowel ◽  
Protease Activated Receptor 2 ◽  
Postinfectious Irritable Bowel Syndrome

Background. The role of protease-activated receptor 2 (PAR2) in the analgesic effect of electroacupuncture (EA) on visceral hypersensitivity (VH) in postinfectious irritable bowel syndrome (PI-IBS) has yet to be elucidated. Aim. In this study, we investigated the molecular mechanisms underlying the analgesic effect of EA in a rat model of PI-IBS. Methods. Visceral hypersensitivity was evaluated by the abdominal withdrawal reflex test before and after administration of the PAR2 agonist, PAR2-AP, and/or EA. The protein expression and mRNA levels of PAR2, CGRP, SP, and TPSP in colon tissues were measured by immunofluorescence, western blot, and RT-PCR. Results. We found that EA could alleviate VH and significantly decrease protein and mRNA levels of PAR2, TPSP, CGRP, and SP in PI-IBS rats. The analgesic effect of EA on VH was slightly reduced in the presence of PAR2-AP. Conclusions. These results suggest that EA alleviates VH symptoms through downregulation of the levels of the TPSP/PAR2/SP/CGRP signaling axis in colon tissues in PI-IBS rats. Together, our data suggests that PAR2 plays a critical role in the analgesic effect of EA on VH in PI-IBS.

Modern possibilities for correction of visceral hypersensitivity in patients with irritable bowel syndrome

2020 ◽  
Vol 0 (2) ◽  
pp. 37-44
Author(s):  
І. М. Skrypnyk ◽  
I. H. Kryvoruchko ◽  
O. F. Gopko ◽  
N. P. Prykhodko
Keyword(s):  
Irritable Bowel Syndrome ◽  
Visceral Hypersensitivity ◽  
Irritable Bowel

Study of visceral hypersensitivity in irritable bowel syndrome

2004 ◽  
Vol 5 (3) ◽  
pp. 103-109 ◽  
Author(s):  
Wen Zhu DONG ◽  
Duo Wu ZOU ◽  
Zhao Shen LI ◽  
Xiao Ping ZOU ◽  
Ai Yong ZHU ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Visceral Hypersensitivity ◽  
Irritable Bowel

scholarly journals PEDIATRIC MANIFESTATION OF IRRITABLE BOWEL SYNDROME AND AYURVEDIC MANAGEMENT: A CASE REPORT

2021 ◽  
pp. 89-93
Author(s):  
Deepak S. Khawale ◽  
Sudha Singh ◽  
Varsha N. Sane
Keyword(s):  
Irritable Bowel Syndrome ◽  
Modern Science ◽  
Healthcare Systems ◽  
Therapeutic Agents ◽  
Complete Relief ◽  
The Past ◽  
Frequent Episodes ◽  
Significant Burden ◽  
Irritable Bowel ◽  
Combined Interventions

Irritable bowel syndrome (IBS) is a common and bothersome disorder in children with an increasing prevalence noted during the past two decades. It has a significant effect on the lives of affected children and their parents and poses a significant burden on healthcare systems. As the patho-physiology of IBS is multifactorial It is difficult to overcome the therapeutic demand of childhood IBS using the same conventional therapeutic agents. The treatment trials are still going on to understand the paediatric IBS and currently focusing on multiple combined interventions in modern science. Background: A 14 years old male patient came to OPD (29/02/2020) having complaint of frequent abdominal pain with increased frequency of motion along with visible mucus discharge whole day since 15 days with frequent episodes since last 2 years. Methodology: In Ayurveda this problem comes under Jatharagni dusti and the present case has been successfully treated as per treatment regimen of Grahani chikitsa. Result: The complete relief has been seen in 6 weeks.

scholarly journals Pharmacology of Antispasmodic Drugs Used in Management of Irritable Bowel Syndrome

Doctor Ru ◽  
2021 ◽  
Vol 20 (4) ◽  
pp. 46-54
Author(s):  
Е.N. Kareva ◽  
◽  
◽  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Russian Federation ◽  
Molecular Mechanisms ◽  
Cell Voltage ◽  
Neural Systems ◽  
Pharmacokinetic Parameters ◽  
Bowel Disorders ◽  
Intestinal Motility Disorders ◽  
The Russian Federation ◽  
Irritable Bowel

Objective of the Review: To describe and compare some pharmacodynamic and pharmacokinetic parameters of antispasmodic drugs used in complex management of irritable bowel syndrome (IBS) in the Russian Federation. Key Points. IBS is a chronic recurrent disease associated with abdominal pain and bowel disorders. The key factors of IBS pathogenesis include intestinal motility disorders and visceral hypersensitivity. Both processes are controlled by endocrine and neural systems. In a target cell, voltage-operated calcium channels mediate neuronal signals for unstriped muscles to contract and for glands to start secreting. Antispasmodic drugs are a group of products that have been used for IBS management for decades. The review describes contemporary idea of molecular mechanisms to control contraction of GIT muscle cells and a comparison of antispasmodic drugs used in complex therapy of IBS in the Russian Federation. Their key pharmacodynamic and pharmacokinetic characteristics are discussed. Conclusion. The fundamental difference of mebeverine (Duspatalin) is its ability to normalise bowel motility in patients with IBS without the need in complete motility suppression. Also, its inability to block muscarinic receptors and stimulate opioid receptors is another advantage in improving the quality of life of patients. Keywords: pharmacodynamics, pharmacokinetics, antispasmodic drugs, therapy of irritable bowel syndrome, mebeverine.

Sign in / Sign up

Export Citation Format

Share Document